Venous thromboembolism prevention in pregnancy and the postpartum period in Primary and Specialized Care
Copyright © 2016 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved..
After noting that there are a number of risk factors for venous thromboembolism disease during pregnancy, it emphasizes primary prevention and treatment of this serious condition during pregnancy and the postpartum period are essential to reduce maternal morbidity and mortality. Low molecular-weight heparins are under the anticoagulant of choice in pregnancy. Your prescription may make both the primary care physician, as the hematologist and obstetrician. As for prescribing terms, an application protocol in both primary and specialized, multidisciplinary care, based on the existing literature on the subject is presented, which indicated that the hypercoagulable disorders associated with some of the risk factors, forced to do thromboprophylaxis with low molecular-weight heparins throughout pregnancy and the postpartum period presented.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Semergen - 43(2017), 6 vom: 28. Sept., Seite 450-456 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Prevención del tromboembolismo venoso durante el embarazo y el puerperio en Atención Primaria y Especializada |
|---|
| Beteiligte Personen: |
Gallo-Vallejo, J L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.05.2018 Date Revised 28.05.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.semerg.2016.08.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM26657095X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM26657095X | ||
| 003 | DE-627 | ||
| 005 | 20231224214828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.semerg.2016.08.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0888.xml |
| 035 | |a (DE-627)NLM26657095X | ||
| 035 | |a (NLM)27889133 | ||
| 035 | |a (PII)S1138-3593(16)30198-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Gallo-Vallejo, J L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Venous thromboembolism prevention in pregnancy and the postpartum period in Primary and Specialized Care |
| 246 | 3 | 3 | |a Prevención del tromboembolismo venoso durante el embarazo y el puerperio en Atención Primaria y Especializada |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.05.2018 | ||
| 500 | |a Date Revised 28.05.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2016 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a After noting that there are a number of risk factors for venous thromboembolism disease during pregnancy, it emphasizes primary prevention and treatment of this serious condition during pregnancy and the postpartum period are essential to reduce maternal morbidity and mortality. Low molecular-weight heparins are under the anticoagulant of choice in pregnancy. Your prescription may make both the primary care physician, as the hematologist and obstetrician. As for prescribing terms, an application protocol in both primary and specialized, multidisciplinary care, based on the existing literature on the subject is presented, which indicated that the hypercoagulable disorders associated with some of the risk factors, forced to do thromboprophylaxis with low molecular-weight heparins throughout pregnancy and the postpartum period presented | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Embarazo | |
| 650 | 4 | |a Enfermedad tromboembólica venosa | |
| 650 | 4 | |a Heparinas de bajo peso molecular | |
| 650 | 4 | |a Low molecular-weight heparins | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Prevención | |
| 650 | 4 | |a Prevention | |
| 650 | 4 | |a Venous thromboembolic disease | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Heparin, Low-Molecular-Weight |2 NLM | |
| 700 | 1 | |a Naveiro-Fuentes, M |e verfasserin |4 aut | |
| 700 | 1 | |a Puertas-Prieto, A |e verfasserin |4 aut | |
| 700 | 1 | |a Gallo-Vallejo, F J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Semergen |d 1998 |g 43(2017), 6 vom: 28. Sept., Seite 450-456 |w (DE-627)NLM095511652 |x 1578-8865 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2017 |g number:6 |g day:28 |g month:09 |g pages:450-456 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semerg.2016.08.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2017 |e 6 |b 28 |c 09 |h 450-456 | ||